GSK's new asthma therapy is approved to improve patient experience
Last Update: 2020-06-19
Search more information of high quality chemicals, good prices and reliable suppliers, visit
This treatment is aimed at severe asthma, which is a kind of asthma that is more serious and still needs a second control method under high-dose glucocorticoid treatmentIn some patients with severe asthma, eosinophil overgrowth has been found, which is one of the causes of lung inflammationIL-5 is the key factor to promote the growth of eosinophilsAs an IL-5 inhibitor, nucala is a kind of "first in class" monoclonal antibody therapyBy inhibiting IL-5, it is expected to reduce the growth of eosinophils and relieve severe asthma symptomsIn 2015, it was approved by the US FDA for the treatment of severe asthma< br / > Image Source: GSK official press release < br / > but in the past, in order to receive treatment, patients had to go to the hospital for injectionIn order to improve the drug experience of patients, the researchers of GSK developed a new way of use, loading nucala into syringes that can be injected by themselves, so that patients or medical staff can inject once every four weeks to control the diseaseIn two open label, single arm, phase 3A clinical trials, based on real-world data analysis, researchers found that after training, patients can successfully learn how to inject themselves for treatmentAnother clinical trial showed that the new way of use was similar to the approved dry powder preparation in pharmacokinetics and pharmacodynamics< br / > "the efficacy of nucala has been well verifiedThis approval also means that patients with severe asthma will be able to use this important treatment at home for the first time" DrHal Barron, GSK's chief scientific officer and President of research and development, said< br / > reference: < br / >  nucala (mepolizumab) gains FDA approval for two new self administration options, retrieved June 6, 2019, from
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to firstname.lastname@example.org
. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.